MedTrace Logo

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

NCT01219192 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-10-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.

Conditions

Interventions

DRUG

M2ES

M2ES IV D1,8,15,21 every 28 days a cycle

DRUG

M2ES

M2ES IV D1,8,15,21, every 28days a cyce.

DRUG

M2ES

M2ES 45mg IV D1,8,15,22 28days a cycle

DRUG

M2ES 60mg

M2ES 60mg IV D1,8,15,22 every 28days a cycle

Sponsors & Collaborators

  • Protgen Ltd

    lead INDUSTRY

Principal Investigators

  • Shunchang JIAO, MD · Chinese PLA General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219192 on ClinicalTrials.gov